Phase 1/2Terminated
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma
- Sponsor
- InterMune (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Interferon Gamma-1b; Rituximab
- Ages
- adults, older adults
- Registry
- NCT00057447
Full record on ClinicalTrials.gov
From the registry
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Primary outcomes
- time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes)
History
Last registry update
Study completion
Registered
Started